PATHFAST®
Cardiac Biomarker Analyzer
A comprehensive menu of lab-quality urgent cardiac tests
High throughput, fast turnaround, and exceptional ease of use
Can run up to 6 whole blood or plasma assays on one patient sample at a time
Easy LIS integration and compact benchtop footprint
Comprehensive menu of lab-quality urgent cardiac tests
- Determines the quantity of Troponin I, NTproBNP, D-Dimer, hsCRP, CK-MB, and Myoglobin present from a single whole blood or plasma sample
- Facilitates critical care decisions for patients with possible acute myocardial infarction, congestive heart failure, deep vein thrombosis, pulmonary embolism, and inflammatory conditions
Troponin I testing: Lab-quality troponin with high analytical precision in minutes
<17 minutes
6% CV at the 99th percentile cutoff of 0.029 ng/ML in under 17 minutes1
Most precise
point of care Troponin I
Based on the latest guidelines, this level of precision enables the use of accelerated diagnostic protocols to optimize patient care and throughput.2
NTproBNP testing: Answers in minutes at the point of care
Gold-standard therapy monitoring for patients with heart failure
Gold-standard therapy monitoring for patients with heart failure. For patients receiving treatment with sacubitril/valsartan (ENTRESTO®), NTproBNP is the preferred and recommended biomarker for assessing risk of cardiovascular death or hospitalization for heart failure (HF).3
For Hospitals
- In the ED: Rapid NTproBNP results inform risk stratification and admission decisions4
- During hospitalization: NTproBNP informs in-hospital management of patients admitted with decompensated CHF5,6 or severe COVID-197
- Prior to discharge: NTproBNP levels can help inform patient prognosis8
For Heart Failure Clinics
- Improve the patient experience: With on-site testing, fragile heart failure patients get the highest quality and most efficient care possible
- Optimize clinic efficiency and drive revenue: HF clinicians can make immediate treatment decisions with less need for follow up and practices can bill for diagnostic services that would otherwise be sent to an outside lab
| Instrument type | Bench-top Cardiac Biomarker Analyzer |
| Throughput | Up to 6 samples or assays per run |
| Measuring time | <17 minutes for to up to six simultaneous samples |
| Sampling material | Whole blood, plasma |
| Measuring principle | Chemiluminescence enzyme immunoassay technology (CLEIA) combined with proprietary Magtration™ technology |
| Reaction temperature | 37.5° C |
| Sample volume | 100 µL |
| Wavelength | 300-650 nm |
| Data storage | Patient data: 1000 |
| QC data | 1800 |
| CAL data | 300 |
| Data transfer | ASTM standard |
| Dimensions | 13.5 in. W x 22.4 in. D x 18.7 in. H |
| Weight | 62 lbs |
| Electrical requirements | 100-240 Vac |
| Monitor/keyboard | LCD Touchscreen |
| Printer/PC | Integrated |
| Interface | RS-232C |
| Calibration | Factory calibration, 2-point calibration every 4 weeks |
| 24-h operation (standby) |  |
Ordering information
Contact us
References:
- Point of care cardiac troponin I and T assay analytical characteristics. IFCC Committee on Clinical Applications of Cardiac Bio-Markers. Accessed June 23, 2023. https://ifcc.web.insd.dk/media/479208/point-of-care-cardiac-troponin-i-and-t-assay-analyticalcharacteristics-designated-by-manufacturer-v092021-1.pdf
- AHA/ACC/ASE/CHEST/SAEM/SCCT/SCMR, Gulati M, Levy PD, et al. Guideline for the evaluation and diagnosis of chest pain: A report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;144(22):e455. doi:10.1161/CIR.0000000000001047
- McKie PM, Burnett JC Jr. NT-proBNP: The gold standard biomarker in heart failure. J Am Coll Cardiol. 2016;68(22):2437-2439. doi:10.1016/j.jacc.2016.10.001
- Cardiac biomarkers and heart failure. American College of Cardiology. May 5, 2023. Accessed August 24, 2023. https://www.acc.org/Latest-in-Cardiology/Articles/2015/02/09/13/00/Cardiac-Biomarkers-and-Heart-Failure
- Kazanegra R, Cheng V, Garcia A, et al. A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study. J Card Fail. 2001;7(1):21-29. doi:10.1054/jcaf.2001.23355
- Amerena PJ, Vathesatogkit DP, Kaul PU, et al. NT-proBNP in Hospital & Ambulatory Settings: Evidence to clinical practice. Cardio Think Lab. September 17, 2020. Accessed August 24, 2023. https://cardiothinklab.com/nt-probnp-in-hospital-ambulatory-settings-evidence-to-clinical-practice/
- Gao L, Jiang D, Wen XS, et al. Prognostic value of NT-proBNP in patients with severe COVID-19. Respir Res. 2020;21(1):83. doi:10.1186/s12931-020-01352-w
- Heidenreich P, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. J Am Coll Cardiol. 202;79(17):e263-e421. doi:10.1016/j.jacc.2021.12.012